Terns Pharmaceuticals Files 8-K
Ticker: TERN · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1831363
Sentiment: neutral
Topics: financial-statements, exhibits, regulation-fd
TL;DR
Terns Pharma filed an 8-K with financial docs, nothing major yet.
AI Summary
On December 3, 2024, Terns Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no specific material event detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Foster City, California.
Why It Matters
This 8-K filing indicates Terns Pharmaceuticals is providing updated financial statements and exhibits, which is standard procedure for public companies to maintain transparency with investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate negative or positive material events.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Foster City, California (location) — Principal Executive Offices
- December 03, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Terns Pharmaceuticals?
The primary purpose of this 8-K filing is to report financial statements and exhibits, along with other events, as of December 3, 2024.
When was Terns Pharmaceuticals, Inc. incorporated?
Terns Pharmaceuticals, Inc. was incorporated in Delaware.
Where are Terns Pharmaceuticals, Inc.'s principal executive offices located?
Terns Pharmaceuticals, Inc.'s principal executive offices are located at 1065 East Hillsdale Blvd., Suite 100, Foster City, California, 94404.
What is the telephone number for Terns Pharmaceuticals, Inc.?
The telephone number for Terns Pharmaceuticals, Inc. is (650) 525-5535.
What is the SEC file number for Terns Pharmaceuticals, Inc.?
The SEC file number for Terns Pharmaceuticals, Inc. is 001-39926.
Filing Stats: 1,748 words · 7 min read · ~6 pages · Grade level 16.2 · Accepted 2024-12-03 07:10:04
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
Filing Documents
- tern-20241203.htm (8-K) — 62KB
- tern-ex99_1.htm (EX-99.1) — 36KB
- img52906712_0.jpg (GRAPHIC) — 31KB
- 0000950170-24-132452.txt ( ) — 271KB
- tern-20241203.xsd (EX-101.SCH) — 26KB
- tern-20241203_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 3 , 2024, Terns Pharmaceuticals, Inc. (the "Company" or "Terns") issued a press release announcing encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating TERN-701 in patients with relapsed/refractory chronic myeloid leukemia (CML). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On December 3, 2024, Terns announced encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating TERN-701 in patients with relapsed/refractory CML. TERN-701 is an investigational, oral, potent, small molecule allosteric BCR-ABL inhibitor being developed for patients with CML. CARDINAL is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics (PK), and efficacy of TERN-701 in patients with relapsed/refractory CML with or without BCR-ABL resistance mutations who were previously treated with at least one 2G tyrosine kinase inhibitor (TKI). Patients previously treated with asciminib are also eligible. Terns believes the emerging safety data show a profile supporting best-in-class potential with no dose limiting toxicities across three completed dose levels, no clinically meaningful changes in liver or pancreatic enzymes, and no AE-related dose reductions or discontinuations at doses that achieve plasma exposures well above target efficacious concentrations. Taken together, the clinical activity and safety data across the dose range in these heavily pre-treated patients with refractory disease support a potential wide therapeutic index that allows for high levels of target coverage with favorable safety/tolerability. As of the October 28, 2024 cutoff date, 15 patients were enrolled across three dose levels of 160mg (n=7), 320mg (n=5), and 400mg (n=3) of TERN-701 dosed once daily, with an overall median treatment duration of 3 months (range 0.79 - 7.5 months). Enrolled patients were heavily pretreated with a median of 4 prior TKIs (range: 1-6) and 80% having had 3 or more TKIs. 47% and 40% of patients, respectively, had previously received ponatinib and asciminib. 73% were not in MMR at baseline, with 60% having a baseline BCR-ABL transcript >1% international scale (IS). As of the data cutoff, 14 of 15 patients remain on treatment. Twelve patients
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Terns Pharmaceuticals, Inc. on December 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: December 3, 2024 By: /s/ Elona Kogan Elona Kogan Chief Legal Officer